Biohaven Pharmaceutical Holding Company Ltd. announced two updates regarding Nurtec® ODT (rimegepant), the only FDA-approved medication to both treat and prevent migraine attacks in adults.
Biohaven has secured additional commercial insurance coverage for Nurtec ODT starting in April 2022 that expands the total number of commercial lives covered to 96 percent or approximately 255 million people via all channels.
The U.S. Food and Drug Administration has approved a label amendment of the Nurtec ODT (rimegepant) Prescribing and Patient Information to include clinical lactation data in the Use in Specific Populations section as it relates to women who are breastfeeding.
The label amendment was approved based on data from a Phase 1, single-center, open-label study evaluating the excretion of a single dose of rimegepant 75 mg in the human milk of healthy lactating women, recently published in the peer-reviewed journal, Breastfeeding Medicine, the official journal of the Academy of Breastfeeding Medicine.
Migraine affects more than 30 million women in America and is the most common cause of disability among women of reproductive age (15 – 49 years).1,2 Often for women with migraine, attacks may subside during pregnancy but resume within 4 weeks of childbirth.3 Given a lack of science-based information about migraine medication for nursing mothers, women are often apprehensive about taking their migraine medications while breastfeeding.